PharmaCorp Rx Inc.
PCRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 175.96% | -64.01% | -189.88% | 5.48% | -111.30% |
| Total Depreciation and Amortization | 146.04% | 239.02% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -179.39% | 17,816.67% | -- | -- | -- |
| Change in Net Operating Assets | 255.17% | -216.41% | 2,971.43% | 118.08% | -473.79% |
| Cash from Operations | 268.90% | -309.91% | 18.09% | 34.12% | -251.07% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -594.43% | -2,707.51% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -594.43% | -2,950.75% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.55% | -166.01% | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -61.54% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.66% | -61.59% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -376.01% | -75.28% | 10,383.33% | 34.12% | -251.07% |